Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism.
Single gene disorders of the autophagy pathway are an emerging, novel and diverse group of multisystem diseases in children. Clinically, these disorders prominently affect the central nervous system at various stages of development, leading to brain malformations, developmental delay, intellectual disability, epilepsy, movement disorders, and neurodegeneration, among others. Frequent early and severe involvement of the central nervous system puts the paediatric neurologist, neurogeneticist, and neurometabolic specialist at the forefront of recognizing and treating these rare conditions. On a molecular level, mutations in key autophagy genes map to different stages of this highly conserved pathway and thus lead to impairment in isolation membrane (or phagophore) and autophagosome formation, maturation, or autophagosome-lysosome fusion. Here we discuss 'congenital disorders of autophagy' as an emerging subclass of inborn errors of metabolism by using the examples of six recently identified monogenic diseases: EPG5-related Vici syndrome, beta-propeller protein-associated neurodegeneration due to mutations in WDR45, SNX14-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome, and three forms of hereditary spastic paraplegia, SPG11, SPG15 and SPG49 caused by SPG11, ZFYVE26 and TECPR2 mutations, respectively. We also highlight associations between defective autophagy and other inborn errors of metabolism such as lysosomal storage diseases and neurodevelopmental diseases associated with the mTOR pathway, which may be included in the wider spectrum of autophagy-related diseases from a pathobiological point of view. By exploring these emerging themes in disease pathogenesis and underlying pathophysiological mechanisms, we discuss how congenital disorders of autophagy inform our understanding of the importance of this fascinating cellular pathway for central nervous system biology and disease. Finally, we review the concept of modulating autophagy as a therapeutic target and argue that congenital disorders of autophagy provide a unique genetic perspective on the possibilities and challenges of pathway-specific drug development.
['Ebrahimi-Fakhari|Darius|D|', 'Saffari|Afshin|A|', 'Wahlster|Lara|L|', 'Lu|Jenny|J|', 'Byrne|Susan|S|', 'Hoffmann|Georg F|GF|', 'Jungbluth|Heinz|H|', 'Sahin|Mustafa|M|']
D061085:Agenesis of Corpus Callosum D001343:Autophagy D020739:Brain Diseases, Metabolic, Inborn D002386:Cataract D006801:Humans D020140:Lysosomal Storage Diseases, Nervous System D008247:Lysosomes D015419:Spastic Paraplegia, Hereditary
autophagy neurodegeneration inborn errors of metabolism mammalian target of rapamycin (mTOR) neurodevelopment